Three patients enrolled in the second dose level cohort completed the first treatment cycle and well tolerated the L-DOS47 therapy.
Patients to be enrolled in the third cohort will receive the next dose level 0.33 micrograms of L-DOS47 per kilogram of patient body weight.
Helix chief executive officer Robert Verhagen said, "L-DOS47 therapy continues to be well tolerated by the patients treated in our first two dose levels."
The immunoconjugate-based drug candidate, L-DOS47, is based on DOS47 technology designed to modify the microenvironmental conditions of cancer cells resulting in their destruction.